Recent advances in the diagnosis, treatment, and prevention of Pneumocystis carinii pneumonia.
In summary, recent advances in our ability to diagnose, treat, and prevent recurrences of pneumocystis pneumonia have significantly improved the clinical management of this infection, especially in HIV-1-infected individuals. As current investigations allow our therapeutic armamentarium in this disease to be strengthened even further, it is likely that pneumocystis pneumonia will pose a diminishing threat to those patients currently most susceptible to this infection.
Davey
R T
RT
Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892.
Masur
H
H
D000163:Acquired Immunodeficiency Syndrome / Q000150:complications; D000970:Antineoplastic Agents / Q000009:adverse effects; D006801:Humans; D009894:Opportunistic Infections / Q000150:complications; D011020:Pneumonia, Pneumocystis / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy / Q000517:prevention & control; D011799:Quinazolines / Q000009:adverse effects; D015662:Trimethoprim, Sulfamethoxazole Drug Combination / Q000009:adverse effects; D016597:Trimetrexate
D000970:Antineoplastic Agents; D011799:Quinazolines; D015662:Trimethoprim, Sulfamethoxazole Drug Combination; D016597:Trimetrexate